Peng Leong, PhD
Chief Business Officer
Peng leads BIOAGE’s efforts to identify and execute strategic transactions that will help the company to convert prioritized drug targets into a portfolio of therapies for human aging. Peng started his career at Chiron Corporation, studying signaling pathways involved in cancer before moving to business development where he acquired rights to novel technologies and drug candidates. While working in healthcare investment banking at CIBC World Markets and Piper Jaffray, he was involved in raising more than US$ 1.4 billion for over 20 biotechnology companies. In his various roles, including at Merck KGaA, Peng has had a leadership role in the acquisition or sale of over US$ 1 billion in pharmaceutical product rights. Recently, as CBO of Kazia Therapeutics, Peng was responsible for strategy and business development, and in-licensed GDC-0084 in Phase II trials for glioblastoma. Peng received his PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley.